Ardelyx Inc. Common Stock (ARDX)
Stock · NASDAQ · Health Care
$3.09as of 10/16/2026
Price chart
Active signals
ARDX Signal Track Record
How signals performed across all stocks →What ARDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -0.8% | 47% | August 6, 2026 |
| Bollinger Band Breakout | 29 | +2.1% | 52% | May 1, 2026 |
| Bollinger Band BreakdownActive now | 15 | +5.1% | 60% | September 14, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +6.9% | 67% | June 25, 2026 |
| Any 20-session window (baseline) | +1.5% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARDX
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, I…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 489
- Website
- www.ardelyx.com/
Fundamentals
- 1-day range
- $3.08$3.27
- Market cap
- $1.20B
- P/E (trailing)
- —
- P/E (forward)
- 10.64
- EPS (trailing)
- $-0.23
- Dividend yield
- —
- Beta
- 0.72
- Avg. volume
- 4.33M
How Ardelyx Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Ardelyx Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
- SVRASavara Inc. Common Stock$4.45▼ 6.12%Market cap $1.19BP/E —$3.38$7.01
- WVEWave Life Sciences Ltd. Ordinary Shares$3.13▼ 1.88%Market cap $1.19BP/E —$3.56$21.73
- CRVSCorvus Pharmaceuticals Inc. Common Stock$9.52▼ 3.35%Market cap $1.17BP/E —$6.39$26.95
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
| SVRA Savara Inc. Common Stock | $1.19B | — | $4.45 | ▼ 6.12% | $3.38$7.01 |
| WVE Wave Life Sciences Ltd. Ordinary Shares | $1.19B | — | $3.13 | ▼ 1.88% | $3.56$21.73 |
| CRVS Corvus Pharmaceuticals Inc. Common Stock | $1.17B | — | $9.52 | ▼ 3.35% | $6.39$26.95 |
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ardelyx Presents Real-World Data Showing Significant Reduction In GI-Related Healthcare Resource Utilization After IBSRELA Initiation, At ACG 2026 Annual Meetingbenzinga · 10/12/2026
- New Strong Sell Stocks for October 9thYahoo · 10/9/2026
- New Strong Sell Stocks for October 7thYahoo · 10/7/2026
- Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026Yahoo · 10/5/2026
- Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer AwardsYahoo · 9/30/2026
- Ardelyx Targets $500M Revenue This Year, Profitability by 2027Yahoo · 9/21/2026
- Ardelyx Q2 2026 Earnings Call TranscriptBenzinga · 9/18/2026
- Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Hohenleitner Susan · August 21, 2026 · Sale1.6K @ $3.86
- Brady James Parker · August 21, 2026 · Sale13.2K @ $3.86
- Reilly Joseph James · August 21, 2026 · Sale2.9K @ $3.86
- Foster Eric Duane · August 21, 2026 · Sale2.6K @ $3.86
- Foster Eric Duane · August 21, 2026 · Sale3.4K @ $3.86
- Foster Eric Duane · August 21, 2026 · Sale2.6K @ $3.86
- Kelliher Mike · August 21, 2026 · Sale2.0K @ $3.86
- Kelliher Mike · August 21, 2026 · Sale2.7K @ $3.86
- Kelliher Mike · August 21, 2026 · Sale3.1K @ $3.86
- Williams Laura A · August 21, 2026 · Sale1.7K @ $3.86
- Williams Laura A · August 21, 2026 · Sale2.4K @ $3.86
- Williams Laura A · August 21, 2026 · Sale3.1K @ $3.86
- Williams Laura A · August 21, 2026 · Sale3.5K @ $3.86
- RAAB MICHAEL · August 21, 2026 · Sale19.2K @ $3.86
- RAAB MICHAEL · August 21, 2026 · Sale8.4K @ $3.86
Institutional Ownership
March 31, 2026
- Total shares held
- 162.33M
- Total value held
- $957.69M
- Institutional holders
- 230
- Unknown21.16M
- Unknown18.04M
- Unknown13.60M
- Unknown10.37M
- Unknown8.37M
- Unknown8.17M
- Unknown6.01M
- Unknown5.23M
- Unknown4.27M
- Unknown3.76M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.